CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT01210222
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:36:39.962434+00:00
Published At: 2017-11-29T00:00:00+00:00
Record Updated At: 2018-02-23
Results Posted At: 2017-11-29
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Endometrial Adenocarcinoma", "Endometrial Adenosquamous Carcinoma", "Endometrial Clear Cell Adenocarcinoma", "Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation", "Endometrial Serous Adenocarcinoma", "Endometrioid Stromal Sarcoma", "Recurrent Uterine Corpus Carcinoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2018-02-23"
protocolSection.identificationModule.nctId: "NCT01210222"
protocolSection.identificationModule.officialTitle: "A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2017-11-29"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.